RGD Reference Report - Expression of cavernous transforming growth factor-beta1 and its type II receptor in patients with erectile dysfunction. - Rat Genome Database

Send us a Message



Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   

Expression of cavernous transforming growth factor-beta1 and its type II receptor in patients with erectile dysfunction.

Authors: Ryu, JK  Han, JY  Chu, YC  Song, SU  Lee, KH  Yoon, SM  Suh, JK  Kim, SJ 
Citation: Ryu JK, etal., Int J Androl. 2004 Feb;27(1):42-9.
RGD ID: 1601627
Pubmed: PMID:14718046   (View Abstract at PubMed)

It has been hypothesized that transforming growth factor-beta1 (TGF-beta1) signalling is involved in erectile dysfunction (ED). This study was undertaken to elucidate in detail whether expression of TGF-beta1 and its type II receptor is clinically related to various causes of ED. Fifty-four patients with ED and 24 potent men were the subjects of this study. After multidisciplinary work-up, the ED was classified as psychogenic (n = 6), neurogenic (n = 15), or vasculogenic (n = 33). In every subject, percutaneous cavernous biopsy was performed using a Biopty gun. Masson's trichrome staining was used to quantitate collagen fibres and immunohistochemical staining to evaluate both TGF-beta1 and its type II receptor by scoring the intensity of immunoreactivity (score 0-6). Collagen fibres were significantly more abundant in men with vasculogenic ED (72.7 +/- 17.7%) than in control subjects (43.3 +/- 11.2%) or those with psychogenic (45.0 +/- 12.2%) or neurogenic (51.3 +/- 20.3%) ED (p < 0.01). Expression of TGF-beta1 was significantly greater in vasculogenic ED (4.3 +/- 1.3) than in the control subjects (2.4 +/- 0.9) or psychogenic ED (2.0 +/- 0.6) groups (p < 0.01). Type II receptor expression was also significantly increased in vasculogenic ED (3.9 +/- 1.3) compared with control (2.2 +/- 0.7) and psychogenic (2.2 +/- 0.8) or neurogenic (2.6 +/- 1.3) ED (p < 0.01). Of the ED groups, both the hyperlipidaemia and the atherosclerosis patients showed significantly more fibrosis than those without the condition (p < 0.05). The abundance of collagen fibres correlated well with both TGF-beta1 expression (gamma = 0.81; p < 0.001) and receptor II expression (gamma = 0.83; p < 0.001). These results suggest that TGF-beta1 and its receptor II pathway are involved in cavernous fibrosis and ED in man. Patients with vascular risk factors such as hyperlipidaemia and atherosclerosis are liable to ED by activation of this pathway.

RGD Manual Disease Annotations    Click to see Annotation Detail View
TermQualifierEvidenceWithReferenceNotesSourceOriginal Reference(s)
vasculogenic impotence  IEP 1601627protein:increased expression:penis erectile tissueRGD 
vasculogenic impotence  ISOTGFBR2 (Homo sapiens)1601627; 1601627protein:increased expression:penis erectile tissueRGD 

Objects Annotated

Genes (Rattus norvegicus)
Tgfbr2  (transforming growth factor, beta receptor 2)

Genes (Mus musculus)
Tgfbr2  (transforming growth factor, beta receptor II)

Genes (Homo sapiens)
TGFBR2  (transforming growth factor beta receptor 2)


Additional Information